Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome

Completed · Phase 4

Conditions studied: Metabolic Syndrome, Insulin Resistance

In brief

The metabolic syndrome is a collection of health risks that includes obesity, high blood pressure, high triglycerides, high blood sugar, low good cholesterol, and resistance to insulin. The purpose of this study is to find out if the medication, rosiglitazone, influences levels of fat cell proteins and alters insulin resistance in nondiabetic persons with the metabolic syndrome. This is an early step to see if a medication, such as rosiglitazone, will be beneficial in people who have the metabolic syndrome.

Key facts

Study ID

NCT00364221

Run by

University of Colorado, Denver

Starts

2004-11-01

Expected to finish

2006-10-01

Last updated by the study team

2012-11-22

Who can join

Age: 30 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Nondiabetic subjects with an NCEP/ATP III diagnosis of the metabolic syndrome

You may not qualify if…

• Statin Medications, liver disease, cardiovascular disease, heart failure, diabetes, chronic kidney disease,

Where it is running

• University of Colorado at Denver and Health Sciences Center General Clinical Research Center — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.